Literature DB >> 18487996

FOXP1 abnormalities in lymphoma: translocation breakpoint mapping reveals insights into deregulated transcriptional control.

Alison Goatly1, Chris M Bacon, Shotaro Nakamura, Hongtao Ye, Insun Kim, Philip J Brown, Agnès Ruskoné-Fourmestraux, Pascale Cervera, Berthold Streubel, Alison H Banham, Ming-Qing Du.   

Abstract

Deregulation of FOXP1 expression plays an important role in lymphoma development although the underlying molecular mechanism is poorly understood. FOXP1 is targeted by chromosome translocations in MALT lymphoma and diffuse large B-cell lymphoma, where high-level protein expression is associated with poor prognosis. Nonetheless, the incidence and nature of FOXP1 abnormalities at both the genetic and protein levels, and their correlation in these lymphomas are not well established. We investigated FOXP1 translocation, copy number change and protein expression in MALT lymphoma (n=321), MALT lymphoma with a diffuse large B-cell lymphoma component (59), nodal diffuse large B-cell lymphoma (64) and extranodal diffuse large B-cell lymphoma (151) by interphase fluorescence in situ hybridization and immunohistochemistry. FOXP1 translocation was found in eight MALT lymphomas and three MALT lymphomas with diffuse large B-cell lymphoma, with all positive cases originating in the stomach. In diffuse large B-cell lymphoma, the translocation was seen in 5 cases originating in the stomach (2), tonsil (1), large intestine (1) and lymph node (1). Immunoglobulin heavy chain gene was the translocation partner in 11 of the 16 positive cases. Fluorescence in situ hybridization mapping revealed FOXP1 breakpoints within the 5' untranslated region of the gene (upstream of exon 6, the first coding exon of full-length FOXP1) in 14 cases, but downstream of exon 6 (most likely upstream of exon 8) in the remaining 2 cases. Three copies of the FOXP1 gene were observed in MALT lymphoma (17%), MALT lymphoma with diffuse large B-cell lymphoma (12%) and diffuse large B-cell lymphoma (32%), including cases with FOXP1 translocation (19%). Immunohistochemistry showed strong/moderate FOXP1 staining in all the cases with FOXP1 translocation. However, FOXP1 expression was independent of FOXP1 translocation or copy number changes. Our findings suggest that (1) FOXP1 translocation may disrupt the full-length FOXP1 transcript and lead to expression of FOXP1 transcript variants with alternate 5' ends and (2) mechanisms other than translocation and copy number changes are also responsible for FOXP1 overexpression in lymphoma.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18487996     DOI: 10.1038/modpathol.2008.74

Source DB:  PubMed          Journal:  Mod Pathol        ISSN: 0893-3952            Impact factor:   7.842


  25 in total

1.  Prognostic markers and gene abnormalities in subgroups of diffuse large B-cell lymphoma: single center experience.

Authors:  Petra Korać; Mara Dominis
Journal:  Croat Med J       Date:  2008-10       Impact factor: 1.351

2.  Solution structure and backbone dynamics of the DNA-binding domain of FOXP1: insight into its domain swapping and DNA binding.

Authors:  Yuan-Ping Chu; Chia-Hao Chang; Jia-Hau Shiu; Yao-Tsung Chang; Chiu-Yueh Chen; Woei-Jer Chuang
Journal:  Protein Sci       Date:  2011-04-11       Impact factor: 6.725

3.  Integrative genomic profiling of human prostate cancer.

Authors:  Barry S Taylor; Nikolaus Schultz; Haley Hieronymus; Anuradha Gopalan; Yonghong Xiao; Brett S Carver; Vivek K Arora; Poorvi Kaushik; Ethan Cerami; Boris Reva; Yevgeniy Antipin; Nicholas Mitsiades; Thomas Landers; Igor Dolgalev; John E Major; Manda Wilson; Nicholas D Socci; Alex E Lash; Adriana Heguy; James A Eastham; Howard I Scher; Victor E Reuter; Peter T Scardino; Chris Sander; Charles L Sawyers; William L Gerald
Journal:  Cancer Cell       Date:  2010-06-24       Impact factor: 31.743

4.  Expression of PIK3CA and FOXP1 in gastric and intestinal non-Hodgkin's lymphoma of mucosa-associated lymphoid tissue type.

Authors:  Linzhu Zhai; Yuanyuan Zhao; Sheng Ye; He Huang; Ying Tian; Qiuliang Wu; Hanliang Lin; Tongyu Lin
Journal:  Tumour Biol       Date:  2011-06-10

5.  FOXP1, an estrogen-inducible transcription factor, modulates cell proliferation in breast cancer cells and 5-year recurrence-free survival of patients with tamoxifen-treated breast cancer.

Authors:  Takashi Shigekawa; Nobuhiro Ijichi; Kazuhiro Ikeda; Kuniko Horie-Inoue; Chikako Shimizu; Shigehira Saji; Kenjiro Aogi; Hitoshi Tsuda; Akihiko Osaki; Toshiaki Saeki; Satoshi Inoue
Journal:  Horm Cancer       Date:  2011-10       Impact factor: 3.869

6.  Downregulation of FOXP1 is required during germinal center B-cell function.

Authors:  Ainara Sagardoy; Jose I Martinez-Ferrandis; Sergio Roa; Karen L Bunting; María Angela Aznar; Olivier Elemento; Rita Shaknovich; Lorena Fontán; Vicente Fresquet; Ignacio Perez-Roger; Eloy F Robles; Linde De Smedt; Xavier Sagaert; Ari Melnick; Jose A Martinez-Climent
Journal:  Blood       Date:  2013-04-11       Impact factor: 22.113

Review 7.  Chronic inflammatory disease, lymphoid tissue neogenesis and extranodal marginal zone B-cell lymphomas.

Authors:  Richard J Bende; Febe van Maldegem; Carel J M van Noesel
Journal:  Haematologica       Date:  2009-07-16       Impact factor: 9.941

8.  New developments in the pathology of malignant lymphoma: a review of the literature published from May to July 2008.

Authors:  J Han van Krieken
Journal:  J Hematop       Date:  2008-09       Impact factor: 0.196

9.  N-terminally truncated FOXP1 protein expression and alternate internal FOXP1 promoter usage in normal and malignant B cells.

Authors:  Philip J Brown; Duncan M Gascoyne; Linden Lyne; Hayley Spearman; Suet Ling Felce; Nora McFadden; Probir Chakravarty; Sharon Barrans; Steven Lynham; Dinis P Calado; Malcolm Ward; Alison H Banham
Journal:  Haematologica       Date:  2016-04-07       Impact factor: 9.941

10.  Gene selection and cancer type classification of diffuse large-B-cell lymphoma using a bivariate mixture model for two-species data.

Authors:  Yuhua Su; Dahlia Nielsen; Lei Zhu; Kristy Richards; Steven Suter; Matthew Breen; Alison Motsinger-Reif; Jason Osborne
Journal:  Hum Genomics       Date:  2013-01-05       Impact factor: 4.639

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.